Advertisement

Bioinformatics Analysis Suggests the Combined Expression of AURKB and KIF18B Being an Important Event in the Development of Clear Cell Renal Cell Carcinoma

  • Qianqian Liu
  • Xiling Zhang
  • Haichao Tang
  • Jinwei Liu
  • Chen Fu
  • Mingli Sun
  • Lin Zhao
  • Minjie Wei
  • Zhaojin YuEmail author
  • Ping WangEmail author
Original Article
  • 70 Downloads

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma with high metastatic rate and high mortality rate, needing to find potential therapeutic targets and develop new therapy methods. The bioinformatics analysis was used in this study to find the targets. Firstly, the expression profile of ccRCC obtained from The Cancer Genome Atlas (TCGA) database and GSE53757 dataset were used to identify the significant up-regulated genes. IL20RB, AURKB and KIF18B with the top efficiency of capable of diagnosis ccRCC from para cancer tissue, were over-expressed in ccRCC samples, and expressed increasedly with the development of ccRCC. There was the closest correlation between AURKB and KIF18B in these three over-expressed genes. AURKB (high) or KIF18B (high) were all significantly correlated with higher T, N, M stage, G grade and shorter overall survival (OS) of ccRCC patients. Furthermore, the ccRCC patients with AURKB (high) + KIF18B (high) showed worse clinical characteristics and prognosis. Multivariate COX regression analysis indicated AURKB (high) and KIF18B (high) were all the independent prognostic risk factor without considering the interaction of AURKB and KIF18B. Moreover, considering the combination of each other, only AURKB (high) + KIF18B (high) expression was an independent prognostic risk factor for ccRCC patients, but not other situations. Collectively, AURKB was closely associated with KIF18B, and the combined expression of AURKB and KIF18B may be of great significance in ccRCC.

Keywords

AURKB KIF18B Clear cell renal cell carcinoma Differentially expressed genes Combined expression 

Abbreviations

ccRCC

Clear cell renal cell carcinoma

TCGA

The Cancer Genome Atlas

GEO

Gene Expression Omnibus

DEGs

Differentially expressed genes

ROC

Receiver operating characteristic

AUC

Area under the curve

OS

Overall survival

Notes

Acknowledgements

This research was funded by the National Natural Science Foundation of China (No. 81601370), the Construction of Translational Medicine Research Center and Collaborative Network in the Area of Bladder Diseases of Liaoning Province (No. 2015225009), the National Natural Science Foundation of China and Liaoning joint fund key program (No. U1608281) and the Double Hundred Program for Shenyang Scientific and Technological Innovation Projects (No. 100040).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424Google Scholar
  2. 2.
    Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L et al (2017) Renal cell carcinoma. Nat Rev Dis Primers 3(17009):9Google Scholar
  3. 3.
    Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ (2018) Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. J Pathol 244(5):525–537Google Scholar
  4. 4.
    Li QK, Pavlovich CP, Zhang H, Kinsinger CR, Chan DW (2019) Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): a critical step towards the personalized care of renal cancers. Semin Cancer Biol 55:8–15Google Scholar
  5. 5.
    Capitanio U, Montorsi F (2016) Renal cancer. Lancet 387:894–906Google Scholar
  6. 6.
    Keefe SM, Nathanson KL, Rathmell WK (2013) The molecular biology of renal cell carcinoma. Semin Oncol 40(4):421–428Google Scholar
  7. 7.
    Fan Y, Ma X, Li H, Gao Y, Huang Q, Zhang Y, Bao X, du Q, Luo G, Liu K, Meng Q, Zhao C, Zhang X (2018) miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating dicer. Int J Cancer 142(3):547–560Google Scholar
  8. 8.
    Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR et al (2013) The cancer genome atlas Pan-Cancer analysis project. Nat Genet 45(10):1113–1120Google Scholar
  9. 9.
    Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF et al (2013) NCBI GEO: archive for functional genomics datasets-update. Nucleic Acids Res 41:D991–D995Google Scholar
  10. 10.
    Wang Z, Yang B, Zhang M, Guo W, Wu Z et al (2018) lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell 33(4):706–720Google Scholar
  11. 11.
    Li B, Wang W, Li Z, Chen Z, Zhi X, Xu J, Li Q, Wang L, Huang X, Wang L, Wei S, Sun G, Zhang X, He Z, Zhang L, Zhang D, Xu H, el-Rifai W, Xu Z (2017) MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett 410:212–227Google Scholar
  12. 12.
    Chen L, Yuan L, Qian K, Qian G, Zhu Y, Wu CL, Dan HC, Xiao Y, Wang X (2018) Identification of biomarkers associated with pathological stage and prognosis of clear cell renal cell carcinoma by co-expression network analysis. Front Physiol 9:399Google Scholar
  13. 13.
    Song J, Peng J, Zhu C, Bai G, Liu Y, Zhu J, Liu J (2018) Identification and validation of two novel prognostic lncRNAs in kidney renal clear cell carcinoma. Cell Physiol Biochem 48(6):2549–2562Google Scholar
  14. 14.
    Atkins MB, Tannir NM (2018) Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev 70:127–137Google Scholar
  15. 15.
    Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI, Kutikov A (2015) Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol 67(1):85–97Google Scholar
  16. 16.
    Yan M, Wang C, He B, Yang M, Tong M et al (2016) Aurora-a kinase: a potent oncogene and target for cancer therapy. Med Res Rev 36(6):1036–1079Google Scholar
  17. 17.
    Al-Khafaji AS, Davies MP, Risk JM, Marcus MW, Koffa M et al (2017) Aurora B expression modulates paclitaxel response in non-small cell lung cancer. Br J Cancer 116(5):592–599Google Scholar
  18. 18.
    Enjoji M, Iida S, Sugita H, Ishikawa T, Uetake H et al (2009) BubR1 and AURKB overexpression are associated with a favorable prognosis in gastric cancer. Mol Med Rep 2(4):589–596Google Scholar
  19. 19.
    Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL, Hsu HC (2010) Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B overexpression in HCC. BMC Cancer 10:461Google Scholar
  20. 20.
    ZhangY JC, Li H, Lv F, Li X et al (2015) Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer. Int J Clin Exp Pathol 8(1):751–757Google Scholar
  21. 21.
    Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, Wang PH, Yuan CC (2009) Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 455(5):431–440Google Scholar
  22. 22.
    Lens SM, Voest EE, Medema RH (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10(12):825–841Google Scholar
  23. 23.
    Tang A, Gao K, Chu L, Zhang R, Yang J et al (2017) Aurora kinases: novel therapy targets in cancers. Oncotarget 8(14):23937–23954Google Scholar
  24. 24.
    Lok W, Klein RQ, Saif MW (2010) Aurora kinase inhibitors as anti-cancer therapy. Anti-Cancer Drugs 21(4):339–350Google Scholar
  25. 25.
    Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A, el-Rifai W (2012) The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 11(3):763–774Google Scholar
  26. 26.
    Cheung CH, Sarvagalla S, Lee JY, Huang YC, Coumar MS (2014) Aurora kinase inhibitor patents and agents in clinical testing: an update (2011-2013). Expert Opin Ther Pat 24(9):1021–1038Google Scholar
  27. 27.
    Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI (2013) Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Investig New Drugs 31(2):370–380Google Scholar
  28. 28.
    Yu Y, Feng YM (2010) The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. Cancer 116(22):5150–5160Google Scholar
  29. 29.
    Lee YM, Kim E, Park M, Moon E, Ahn SM, Kim W, Hwang KB, Kim YK, Choi W, Kim W (2010) Cell cycle-regulated expression and subcellular localization of a kinesin-8 member human KIF18B. Gene 466(1–2):16–25Google Scholar
  30. 30.
    Wu Y, Wang A, Zhu B, Huang J, Lu E (2018) KIF18B promotes tumor progression through activating the Wnt/β-catenin pathway in cervical cancer. Onco Targets Ther 11:1707–1720Google Scholar
  31. 31.
    Itzel T, Scholz P, Maass T, Krupp M, Marquardt JU, Strand S, Becker D, Staib F, Binder H, Roessler S, Wang XW, Thorgeirsson S, Müller M, Galle PR, Teufel A (2015) Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis. Bioinformatics 31(2):216–224Google Scholar
  32. 32.
    Tanenbaum ME, Macurek L, van der Vaart B, Galli M, Akhmanova A, Medema RH (2011) A complex of Kif18b and MCAK promotes microtubule depolymerization and is negatively regulated by Aurora kinases. Curr Biol 21(16):1356–1365Google Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  • Qianqian Liu
    • 1
    • 2
  • Xiling Zhang
    • 3
  • Haichao Tang
    • 1
    • 2
  • Jinwei Liu
    • 1
    • 2
  • Chen Fu
    • 1
    • 2
  • Mingli Sun
    • 1
    • 2
  • Lin Zhao
    • 1
    • 2
  • Minjie Wei
    • 1
    • 2
  • Zhaojin Yu
    • 1
    • 2
    Email author
  • Ping Wang
    • 3
    Email author
  1. 1.Department of Pharmacology, School of PharmacyChina Medical UniversityShenyangChina
  2. 2.Liaoning Engineering Technology Research Center for the Research, Development and Industrialization of Innovative Peptide DrugsChina Medical UniversityShenyangChina
  3. 3.Department of UrologyThe Fourth Affiliated Hospital of China Medical UniversityShenyangChina

Personalised recommendations